Article · 2022
Editor
Angelica Merlot
Molecular Pharmacology and Pathology, The University of Sydney, Australia, Faculty of Medicine
About
As published by the journal they serve.
Dr. Angelica Merlot is a Postdoctoral Research Associate in the Pathology Department of the University of Sydney. She heads the Cancer Therapeutics Group within the Molecular Pharmacology and Pathology Program. During her PhD, she investigated the pharmacological mechanisms of action and membrane transport of anti-cancer thiosemicarbazones. The most potent agent of this class is entering clinical trials in 2016. Angelica is interested in improving the targeting and pharmacological complications of cancer therapies that cause toxicity and drug resistance. Her current research focuses on the characterization of the endoplasmic reticulum stress pathways in cancer and modulating these signals to induce cancer cell death and inhibit metastasis.
Research interests
Journals they serve
The seats these journals name them in.
- Clinical Pharmacology & BiopharmaceuticsEditor
- Clinical Pharmacology & BiopharmaceuticsEditorial Board Member
Articles we hold
Articles in the journals they serve whose byline carries this name.
Article · 2023
Evaluating the Efficacy and Safety of Novel Therapeutic in Phase 3 Clinical Trial
Article · 2023
Evaluating the Efficacy and Safety of Novel Therapeutic in Phase 3 Clinical Trial
Article · 2023
Current Strategies for Treating Hepatocellular Carcinoma in Clinical Trial
Article · 2023
Current Strategies for Treating Hepatocellular Carcinoma in Clinical Trial
Article · 2014
Receptor Recognition and Lysosomal Targeting to Enhance Cytotoxicity of Novel Anti-Cancer Agents that Bind Iron and Copper
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.